Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.
EXECUTIVE BIOGRAPHIES

Dr. Janet Greeson
Chief Executive Officer, President and Director

Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that transformed Samaritan from a "one drug" Company to an innovative "Drug Development Pipeline" Biopharmaceutical Company. She strategically created a long-term value and growth model, with the Samaritan/Georgetown University collaboration; and intends to duplicate this growth model with other top tier Universities, as a solid strategy to continually build Samaritan's value and sustain its future profitability.

Dr. Greeson is a successful healthcare professional with over two decades of corporate experience focused on emerging growth situations, leadership development, and mergers and acquisitions. Although she has worked with Samaritan for nine years, as CEO for the past four years she has demonstrated a relentless perseverance and determination to succeed in the face of unrelenting change. She is extremely motivated and equipped to attack problems and seize realistic opportunities, with capability, courage and confidence.

Dr. Greeson is a co-inventor of 18 patent applications, and presently has nine "peer reviewed" journal publications. She is a best selling author of "It's Not What You Are Eating, It's What's Eating You"; and a renowned public speaker, whose guest appearances on numerous radio and TV Talk shows, has opened the door to tell the Samaritan story, in a concise and professional manner.

Dr. Greeson is an experienced growth "Model" developer. In the past, Dr. Greeson developed model "Addiction Rehab Programs" for the US Navy, and went on privately, to develop and grow a nationwide "inpatient treatment program model" which she later sold to Columbia/HCA (NYSE:COL).

Dr. Greeson has an eclectic past, once working with Mother Theresa and was privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994, winning the primary without spending a dollar to campaign. She currently fulfills her altruistic energies with the Samaritan Innovative Science Foundation.

Dr. Greeson holds a BA, from Florida Technological University 1978; an MA from Rollins College 1979; a PhD from Columbia Pacific University 1987.

Dr. Greeson devotes substantially all of her time to the affairs of Samaritan Pharmaceuticals.

Journals:

1. Yao Z, Brown RC, Teper G, Greeson J, Papadopoulos V. (2002) 22R-hydroxycholesterol protects neuronal cells from ß-amyloid-induced cytotoxicity by binding to ß-amyloid peptide. Journal of Neurochemistry, 83:1110-1119.

2. Xu, J, Lecanu L, Yao Z, Greeson J, Papadopoulos V (2003) Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid and activity. J Pharmacology & Experimental Therapeutics, in press.

3. Lecanu L, Yao W, Teper GL, Yao ZX, Greeson J, Papadopoulos V (2003) Identification of naturally occurring 22R-hydroxycholesterol derivatives preventing b-amyloid-induced neurotoxicity. Steroids, in press.

4. Diallo S, Lecanu L, Greeson J, Papadopoulos V (2003) A capillary gas chromatography/mass spectrometric method for the quantification of hydroxysteroids in human plasma. Analytical Biochemistry, in press.

Patents:

1. Papadopoulos V., Lecanu L., Greeson J, Teeper G. Spirostanol-containing compounds and plant extract components and methods for reducing ß-amyloid-induced cytotoxicity and therapies based thereon.

Back to Board of Directors

Back to Profiles

Partnering
Opportunities